The University of Chicago Header Logo

Connection

Marina Chiara Garassino to Antibodies, Monoclonal, Humanized

Back to Details
This is a "connection" page, showing publications Marina Chiara Garassino has written about Antibodies, Monoclonal, Humanized.
Marina Chiara Garassino
Connection Strength
4.895
Antibodies, Monoclonal, Humanized
  1. Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study. J Clin Oncol. 2024 Aug 20; 42(24):2860-2872.
    View in: PubMed
    Score: 0.607
  2. Pembrolizumab plus Chemotherapy in Lung Cancer. N Engl J Med. 2018 09 13; 379(11):e18.
    View in: PubMed
    Score: 0.408
  3. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med. 2018 May 31; 378(22):2078-2092.
    View in: PubMed
    Score: 0.397
  4. Determinants of 5-year survival in patients with advanced NSCLC with PD-L1=50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry. J Immunother Cancer. 2025 Feb 04; 13(2).
    View in: PubMed
    Score: 0.159
  5. Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2024 Sep 28; 404(10459):1240-1252.
    View in: PubMed
    Score: 0.155
  6. The KEYVIBE program: vibostolimab and pembrolizumab for the treatment of advanced malignancies. Future Oncol. 2024; 20(27):1983-1991.
    View in: PubMed
    Score: 0.155
  7. Pembrolizumab with platinum-based chemotherapy with or without epacadostat as first-line treatment for metastatic non-small cell lung cancer: a randomized, partially double-blind, placebo-controlled phase II study. BMC Cancer. 2024 Jul 25; 23(Suppl 1):1250.
    View in: PubMed
    Score: 0.153
  8. Atezolizumab Plus Carboplatin and Etoposide in Patients with Untreated Extensive-Stage Small-Cell Lung Cancer: Interim Results of the MAURIS Phase IIIb Trial. Oncologist. 2024 May 03; 29(5):e690-e698.
    View in: PubMed
    Score: 0.151
  9. Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up. J Thorac Oncol. 2024 Aug; 19(8):1228-1241.
    View in: PubMed
    Score: 0.151
  10. Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden. Clin Cancer Res. 2024 02 16; 30(4):824-835.
    View in: PubMed
    Score: 0.149
  11. Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2021 10; 22(10):1438-1447.
    View in: PubMed
    Score: 0.126
  12. Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series. Eur J Intern Med. 2021 11; 93:87-94.
    View in: PubMed
    Score: 0.125
  13. Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy. Eur J Cancer. 2021 06; 150:224-231.
    View in: PubMed
    Score: 0.123
  14. Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. J Immunother Cancer. 2021 04; 9(4).
    View in: PubMed
    Score: 0.122
  15. Shifting From a "One Size Fits All" to a Tailored Approach for Immune-Related Adverse Events. J Thorac Oncol. 2021 02; 16(2):183-186.
    View in: PubMed
    Score: 0.120
  16. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). J Clin Oncol. 2021 02 20; 39(6):619-630.
    View in: PubMed
    Score: 0.120
  17. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021 01; 22(1):51-65.
    View in: PubMed
    Score: 0.119
  18. Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy. Clin Lung Cancer. 2021 03; 22(2):e180-e192.
    View in: PubMed
    Score: 0.118
  19. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials. Cancer. 2020 11 15; 126(22):4867-4877.
    View in: PubMed
    Score: 0.117
  20. Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score =50% treated with front-line pembrolizumab. Acta Oncol. 2020 Sep; 59(9):1058-1063.
    View in: PubMed
    Score: 0.115
  21. First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status. Eur J Cancer. 2020 05; 130:155-167.
    View in: PubMed
    Score: 0.114
  22. Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2020 05 10; 38(14):1505-1517.
    View in: PubMed
    Score: 0.113
  23. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020 03; 21(3):387-397.
    View in: PubMed
    Score: 0.113
  24. Multiple sclerosis associated with pembrolizumab in a patient with non-small cell lung cancer. J Neurol. 2019 12; 266(12):3163-3166.
    View in: PubMed
    Score: 0.110
  25. Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out. Cancer Treat Rev. 2019 May; 75:39-51.
    View in: PubMed
    Score: 0.106
  26. Should KRAS mutations be considered an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab? J Clin Oncol. 2008 May 20; 26(15):2600; author reply 2601-2.
    View in: PubMed
    Score: 0.050
  27. Bevacizumab for non-small-cell lung cancer. N Engl J Med. 2007 Mar 29; 356(13):1373; author reply 1374-5.
    View in: PubMed
    Score: 0.046
  28. Development and clinical indications of cetuximab. Int J Biol Markers. 2007 Jan-Mar; 22(1 Suppl 4):S40-6.
    View in: PubMed
    Score: 0.045
  29. Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study. Mol Cancer. 2024 May 30; 23(1):115.
    View in: PubMed
    Score: 0.038
  30. Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial. J Clin Oncol. 2024 Jan 10; 42(2):192-204.
    View in: PubMed
    Score: 0.037
  31. Brief Report: Exploratory Analysis of Maintenance Therapy in Patients With Extensive-Stage SCLC Treated First Line With Atezolizumab Plus Carboplatin and Etoposide. J Thorac Oncol. 2022 09; 17(9):1122-1129.
    View in: PubMed
    Score: 0.033
  32. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open. 2022 04; 7(2):100408.
    View in: PubMed
    Score: 0.033
  33. Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407. J Thorac Oncol. 2021 11; 16(11):1883-1892.
    View in: PubMed
    Score: 0.031
  34. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189. Ann Oncol. 2021 07; 32(7):881-895.
    View in: PubMed
    Score: 0.031
  35. Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial. J Thorac Oncol. 2021 08; 16(8):1369-1378.
    View in: PubMed
    Score: 0.031
  36. Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC). Clin Lung Cancer. 2021 07; 22(4):301-312.e8.
    View in: PubMed
    Score: 0.030
  37. Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial. Ann Oncol. 2020 02; 31(2):310-317.
    View in: PubMed
    Score: 0.028
  38. Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer. Eur J Cancer. 2019 02; 108:120-128.
    View in: PubMed
    Score: 0.026
  39. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. Lancet Oncol. 2018 11; 19(11):1468-1479.
    View in: PubMed
    Score: 0.026
  40. RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma. Clin Lung Cancer. 2018 09; 19(5):e811-e814.
    View in: PubMed
    Score: 0.025
  41. Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). J Clin Oncol. 2017 Aug 20; 35(24):2781-2789.
    View in: PubMed
    Score: 0.023
  42. Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer. Curr Oncol Rep. 2016 09; 18(9):59.
    View in: PubMed
    Score: 0.022
  43. Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306. Ann Oncol. 2012 Oct; 23(10):2771-2772.
    View in: PubMed
    Score: 0.017
  44. Risk/benefit profile of bevacizumab in metastatic colon cancer: a systematic review and meta-analysis. Dig Liver Dis. 2011 Apr; 43(4):286-94.
    View in: PubMed
    Score: 0.015
  45. Role of cetuximab in the treatment of patients with NSCLC: are we throwing out the baby with the bath water? J Clin Oncol. 2010 Sep 20; 28(27):e467; author reply e468.
    View in: PubMed
    Score: 0.014
  46. Cetuximab for metastatic colorectal cancer. N Engl J Med. 2009 Jul 02; 361(1):95; author reply 96-7.
    View in: PubMed
    Score: 0.013
  47. Cetuximab for colorectal cancer. N Engl J Med. 2008 Mar 13; 358(11):1196; author reply 1196-7.
    View in: PubMed
    Score: 0.012
  48. Predicting response of molecular targeted therapies: a still possible challenge? Ann Oncol. 2008 May; 19(5):829-30.
    View in: PubMed
    Score: 0.012
  49. Response of thymoma to cetuximab. Lancet Oncol. 2007 May; 8(5):449-50.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.